Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$7.13 - $9.49 $3.09 Million - $4.11 Million
-433,000 Reduced 74.28%
149,900 $1.35 Million
Q3 2023

Nov 14, 2023

SELL
$7.77 - $12.27 $1.38 Million - $2.17 Million
-177,200 Reduced 23.31%
582,900 $4.53 Million
Q2 2023

Aug 14, 2023

BUY
$8.96 - $11.69 $4.23 Million - $5.52 Million
471,800 Added 163.65%
760,100 $7.36 Million
Q1 2023

May 15, 2023

BUY
$5.94 - $11.27 $1.24 Million - $2.36 Million
209,100 Added 264.02%
288,300 $3.16 Million
Q4 2022

Feb 14, 2023

BUY
$4.11 - $8.14 $61,650 - $122,100
15,000 Added 23.36%
79,200 $342,000
Q3 2022

Nov 14, 2022

BUY
$6.66 - $12.39 $427,572 - $795,438
64,200 New
64,200 $483,000
Q4 2020

Feb 16, 2021

SELL
$12.94 - $16.05 $734,992 - $911,640
-56,800 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$13.19 - $16.66 $400,976 - $506,464
-30,400 Reduced 34.86%
56,800 $837,000
Q2 2020

Aug 14, 2020

BUY
$14.12 - $18.33 $189,208 - $245,621
13,400 Added 18.16%
87,200 $1.42 Million
Q1 2020

May 15, 2020

BUY
$11.34 - $21.46 $836,892 - $1.58 Million
73,800 New
73,800 $1.07 Million
Q2 2019

Aug 14, 2019

SELL
$6.05 - $6.75 $65,945 - $73,575
-10,900 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$6.06 - $7.64 $66,054 - $83,276
10,900 New
10,900 $71,000
Q3 2018

Nov 14, 2018

SELL
$5.27 - $6.64 $136,493 - $171,976
-25,900 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$5.06 - $6.36 $60,719 - $76,320
-12,000 Reduced 31.66%
25,900 $146,000
Q1 2018

May 15, 2018

SELL
$4.85 - $5.99 $50,924 - $62,895
-10,500 Reduced 21.69%
37,900 $197,000
Q4 2017

Feb 14, 2018

SELL
$4.53 - $7.09 $32,163 - $50,339
-7,100 Reduced 12.79%
48,400 $219,000
Q3 2017

Nov 14, 2017

BUY
$5.71 - $6.9 $316,905 - $382,950
55,500
55,500 $348,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.